Antigenicity of a polysaccharide vaccine from neisseria meningitidis administered intranasally

Richard P. Wenzel, John R. Mitzel, John A. Davies, Earl A. Edwards, Carl Berling, David P. McCormick, Walter E. Beam

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Polysaccharide vaccine from group C Neisseria meningitidis was administered in- tranasally to three groups of approximately 20 men each. The antigen, 50 pg (groups I and II) or 200 pg (group III), was given in one dose, and the subjects were studied for approximately five weeks. Although slight tearing and conjunctival redness was observed in most subjects after vaccination, only three men in the first group complained of mild ocular and nasal symptoms. No other allergic or toxic reactions were observed. Two weeks after vaccination titers of serum HA antibody to group C meningococci of 4:8 were observed in 45%, 29%, and 70% of men in groups I, II, and III, respectively. A rise in antibody after vaccination was also detected by the bactericidal test, but no detectable complement-fixing antibody developed. The intranasal vaccine did not produce significant rises in titer of local nasal antibody. Three weeks after vaccination with the 200-pg dose (P =.029), fewer vaccinees than controls yielded group C organisms on culture. Comparison of vaccinees with natural carriers of meningococci showed that the antibody response to natural nasopharyngeal infection was approximately three times greater than that conferred by the 200-pg dose of vaccine. Although not recommended to replace the parenteral vaccine, intranasal vaccination offers a safe method for study of the pathogenesis of meningococcal infection and is the best model available to study the role of local antibody in immunity.

Original languageEnglish (US)
Pages (from-to)31-40
Number of pages10
JournalJournal of Infectious Diseases
Volume128
Issue number1
DOIs
StatePublished - 1973
Externally publishedYes

Fingerprint

Neisseria meningitidis
Polysaccharides
Vaccination
Vaccines
Antibodies
Nose
Meningococcal Infections
Poisons
Antibody Formation
Immunity
Antigens
Control Groups
Infection
Serum

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Wenzel, R. P., Mitzel, J. R., Davies, J. A., Edwards, E. A., Berling, C., McCormick, D. P., & Beam, W. E. (1973). Antigenicity of a polysaccharide vaccine from neisseria meningitidis administered intranasally. Journal of Infectious Diseases, 128(1), 31-40. https://doi.org/10.1093/infdis/128.1.31

Antigenicity of a polysaccharide vaccine from neisseria meningitidis administered intranasally. / Wenzel, Richard P.; Mitzel, John R.; Davies, John A.; Edwards, Earl A.; Berling, Carl; McCormick, David P.; Beam, Walter E.

In: Journal of Infectious Diseases, Vol. 128, No. 1, 1973, p. 31-40.

Research output: Contribution to journalArticle

Wenzel, RP, Mitzel, JR, Davies, JA, Edwards, EA, Berling, C, McCormick, DP & Beam, WE 1973, 'Antigenicity of a polysaccharide vaccine from neisseria meningitidis administered intranasally', Journal of Infectious Diseases, vol. 128, no. 1, pp. 31-40. https://doi.org/10.1093/infdis/128.1.31
Wenzel, Richard P. ; Mitzel, John R. ; Davies, John A. ; Edwards, Earl A. ; Berling, Carl ; McCormick, David P. ; Beam, Walter E. / Antigenicity of a polysaccharide vaccine from neisseria meningitidis administered intranasally. In: Journal of Infectious Diseases. 1973 ; Vol. 128, No. 1. pp. 31-40.
@article{6937aa1dda1447d782ed4b955d372457,
title = "Antigenicity of a polysaccharide vaccine from neisseria meningitidis administered intranasally",
abstract = "Polysaccharide vaccine from group C Neisseria meningitidis was administered in- tranasally to three groups of approximately 20 men each. The antigen, 50 pg (groups I and II) or 200 pg (group III), was given in one dose, and the subjects were studied for approximately five weeks. Although slight tearing and conjunctival redness was observed in most subjects after vaccination, only three men in the first group complained of mild ocular and nasal symptoms. No other allergic or toxic reactions were observed. Two weeks after vaccination titers of serum HA antibody to group C meningococci of 4:8 were observed in 45{\%}, 29{\%}, and 70{\%} of men in groups I, II, and III, respectively. A rise in antibody after vaccination was also detected by the bactericidal test, but no detectable complement-fixing antibody developed. The intranasal vaccine did not produce significant rises in titer of local nasal antibody. Three weeks after vaccination with the 200-pg dose (P =.029), fewer vaccinees than controls yielded group C organisms on culture. Comparison of vaccinees with natural carriers of meningococci showed that the antibody response to natural nasopharyngeal infection was approximately three times greater than that conferred by the 200-pg dose of vaccine. Although not recommended to replace the parenteral vaccine, intranasal vaccination offers a safe method for study of the pathogenesis of meningococcal infection and is the best model available to study the role of local antibody in immunity.",
author = "Wenzel, {Richard P.} and Mitzel, {John R.} and Davies, {John A.} and Edwards, {Earl A.} and Carl Berling and McCormick, {David P.} and Beam, {Walter E.}",
year = "1973",
doi = "10.1093/infdis/128.1.31",
language = "English (US)",
volume = "128",
pages = "31--40",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Antigenicity of a polysaccharide vaccine from neisseria meningitidis administered intranasally

AU - Wenzel, Richard P.

AU - Mitzel, John R.

AU - Davies, John A.

AU - Edwards, Earl A.

AU - Berling, Carl

AU - McCormick, David P.

AU - Beam, Walter E.

PY - 1973

Y1 - 1973

N2 - Polysaccharide vaccine from group C Neisseria meningitidis was administered in- tranasally to three groups of approximately 20 men each. The antigen, 50 pg (groups I and II) or 200 pg (group III), was given in one dose, and the subjects were studied for approximately five weeks. Although slight tearing and conjunctival redness was observed in most subjects after vaccination, only three men in the first group complained of mild ocular and nasal symptoms. No other allergic or toxic reactions were observed. Two weeks after vaccination titers of serum HA antibody to group C meningococci of 4:8 were observed in 45%, 29%, and 70% of men in groups I, II, and III, respectively. A rise in antibody after vaccination was also detected by the bactericidal test, but no detectable complement-fixing antibody developed. The intranasal vaccine did not produce significant rises in titer of local nasal antibody. Three weeks after vaccination with the 200-pg dose (P =.029), fewer vaccinees than controls yielded group C organisms on culture. Comparison of vaccinees with natural carriers of meningococci showed that the antibody response to natural nasopharyngeal infection was approximately three times greater than that conferred by the 200-pg dose of vaccine. Although not recommended to replace the parenteral vaccine, intranasal vaccination offers a safe method for study of the pathogenesis of meningococcal infection and is the best model available to study the role of local antibody in immunity.

AB - Polysaccharide vaccine from group C Neisseria meningitidis was administered in- tranasally to three groups of approximately 20 men each. The antigen, 50 pg (groups I and II) or 200 pg (group III), was given in one dose, and the subjects were studied for approximately five weeks. Although slight tearing and conjunctival redness was observed in most subjects after vaccination, only three men in the first group complained of mild ocular and nasal symptoms. No other allergic or toxic reactions were observed. Two weeks after vaccination titers of serum HA antibody to group C meningococci of 4:8 were observed in 45%, 29%, and 70% of men in groups I, II, and III, respectively. A rise in antibody after vaccination was also detected by the bactericidal test, but no detectable complement-fixing antibody developed. The intranasal vaccine did not produce significant rises in titer of local nasal antibody. Three weeks after vaccination with the 200-pg dose (P =.029), fewer vaccinees than controls yielded group C organisms on culture. Comparison of vaccinees with natural carriers of meningococci showed that the antibody response to natural nasopharyngeal infection was approximately three times greater than that conferred by the 200-pg dose of vaccine. Although not recommended to replace the parenteral vaccine, intranasal vaccination offers a safe method for study of the pathogenesis of meningococcal infection and is the best model available to study the role of local antibody in immunity.

UR - http://www.scopus.com/inward/record.url?scp=0015876880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015876880&partnerID=8YFLogxK

U2 - 10.1093/infdis/128.1.31

DO - 10.1093/infdis/128.1.31

M3 - Article

VL - 128

SP - 31

EP - 40

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 1

ER -